3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Enrolling by invitation
1
Completed
1
Sponsor Class
INDUSTRY
4
OTHER
2
NETWORK
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Conditions
Breast Neoplasms
852
Neoplasms
643
Prostatic Neoplasms
439
Lung Neoplasms
359
Colorectal Neoplasms
327
Carcinoma, Non-Small-Cell Lung
318
Leukemia, Myeloid, Acute
251
Pancreatic Neoplasms
218
Brain Neoplasms
202
Multiple Myeloma
198
Neoplasm Metastasis
191
Carcinoma, Hepatocellular
178
Head and Neck Neoplasms
176
Glioblastoma
167
Precursor Cell Lymphoblastic Leukemia-Lymphoma
166
Melanoma
153
Ovarian Neoplasms
149
Squamous Cell Carcinoma of Head and Neck
148
Rectal Neoplasms
134
Recurrence
132
Hematologic Neoplasms
125
Sarcoma
124
Uterine Cervical Neoplasms
117
Stomach Neoplasms
116
Carcinoma, Renal Cell
115
Triple Negative Breast Neoplasms
114
Glioma
114
Motor Activity
100
Myelodysplastic Syndromes
96
Esophageal Neoplasms
96
Interventions
pembrolizumab
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Immunoproliferative Disorders
×
90 days
×
Clear all
NCT04996706
2026-05-26
LEO
Mayo Clinic
Enrolling by invitation
21,000 enrolled
NCT03349450
2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2
Completed
25 enrolled
18 charts